News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Raymond James and Guggenheim Stay Bullish on Alumis (ALMS) After Trial Results [Yahoo! Finance]

Alumis (ALMS) had its price target raised by Oppenheimer Holdings, Inc. from $50.00 to $55.00. They now have an "outperform" rating on the stock.

Alumis (ALMS) had its "buy" rating reaffirmed by Chardan Capital. They now have a $38.00 price target on the stock.

Alumis (ALMS) had its price target lowered by HC Wainwright from $40.00 to $25.00. They now have a "buy" rating on the stock.

Alumis Spotlights Phase III Psoriasis Data for Envudeucitinib, Teases NDA and Lupus Readout [Yahoo! Finance]

Form SCHEDULE 13G ALUMIS INC. Filed by: Deep Track Capital, LP

Form 4 ALUMIS INC. For: Apr 01 Filed by: Foresite Labs, LLC

Form 4 ALUMIS INC. For: Apr 01 Filed by: Foresite Labs Management I, LLC

Form 4 ALUMIS INC. For: Apr 01 Filed by: Tananbaum James B.

Form SCHEDULE 13D/A ALUMIS INC. Filed by: Foresite Capital Fund VI LP

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}